Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 1 (2022)
Original paper
Submitted: 2021-09-30
Accepted: 2021-11-07
Published online: 2022-02-15
View PDF Download PDF file
Get Citation

The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes

Jarosław Sobiś1, Łukasz Kunert1, Monika Rykaczewska-Czerwińska2, Elżbieta Świętochowska3, Piotr Gorczyca1
DOI: 10.5603/EP.a2021.0110
·
Pubmed: 35381103
·
Endokrynol Pol 2022;73(1):35-42.
Affiliations
  1. Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
  2. Chair and Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
  3. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland

open access

Vol 73, No 1 (2022)
Original Paper
Submitted: 2021-09-30
Accepted: 2021-11-07
Published online: 2022-02-15

Abstract

Introduction: The aim of this study was to test the effect of aripiprazole on leptin, insulin, acute phase proteins, and selected cytokines levels in patients with chronic schizophrenia. Additionally, levels of leptin, insulin, acute phase proteins, and cytokines were compared with body mass and body composition indexes.

Material and methods: Levels of leptin, insulin, serum amyloid A (SAA), tumour necrosis factor alpha (TNF-α), and interleukins 17A (IL-17A) and 18 (IL-18) in blood serum were measured for 17 patients before and after 28 days of administering aripiprazole by means of enzyme-linked immunosorbent assay (ELISA). Before and after the study, body mass and waist circumference (WC) were also measured, and body mass index (BMI) and body fat percentage (BF%) were estimated. The sex of each patient was taken into account.

Results: After administration of aripiprazole the reduction of levels of leptin, insulin, SAA, and TNF-a were statistically significant, similarly to body mass reduction and decrease in WC, BMI, and BF%, which were also statistically significant. A positive correlation between leptin and BF% and negative correlation between insulin and body mass and body composition indexes were observed before and after the study. High sensitivity C-reactive protein (hsCRP) and  hsCRP/albumin positively correlated with BMI before the treatment. In the group of women a statistically significant positive correlation between TNF-α and IL-17A and body mass and body composition indexes was observed, and in the group of men a negative correlation between IL-18 and BMI, WC, and BF% was noted.

Conclusions: The effect of aripiprazole is connected to its anti-inflammatory activity. A 28-day treatment resulted in reduction of adipose tissue, and in the group of women it returned their leptin sensitivity to normal levels. A change of psychotropic treatment and administration of aripiprazole reduces cardiometabolic risks.

Abstract

Introduction: The aim of this study was to test the effect of aripiprazole on leptin, insulin, acute phase proteins, and selected cytokines levels in patients with chronic schizophrenia. Additionally, levels of leptin, insulin, acute phase proteins, and cytokines were compared with body mass and body composition indexes.

Material and methods: Levels of leptin, insulin, serum amyloid A (SAA), tumour necrosis factor alpha (TNF-α), and interleukins 17A (IL-17A) and 18 (IL-18) in blood serum were measured for 17 patients before and after 28 days of administering aripiprazole by means of enzyme-linked immunosorbent assay (ELISA). Before and after the study, body mass and waist circumference (WC) were also measured, and body mass index (BMI) and body fat percentage (BF%) were estimated. The sex of each patient was taken into account.

Results: After administration of aripiprazole the reduction of levels of leptin, insulin, SAA, and TNF-a were statistically significant, similarly to body mass reduction and decrease in WC, BMI, and BF%, which were also statistically significant. A positive correlation between leptin and BF% and negative correlation between insulin and body mass and body composition indexes were observed before and after the study. High sensitivity C-reactive protein (hsCRP) and  hsCRP/albumin positively correlated with BMI before the treatment. In the group of women a statistically significant positive correlation between TNF-α and IL-17A and body mass and body composition indexes was observed, and in the group of men a negative correlation between IL-18 and BMI, WC, and BF% was noted.

Conclusions: The effect of aripiprazole is connected to its anti-inflammatory activity. A 28-day treatment resulted in reduction of adipose tissue, and in the group of women it returned their leptin sensitivity to normal levels. A change of psychotropic treatment and administration of aripiprazole reduces cardiometabolic risks.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

aripiprazole; chronic schizophrenia; leptin

About this article
Title

The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes

Journal

Endokrynologia Polska

Issue

Vol 73, No 1 (2022)

Article type

Original paper

Pages

35-42

Published online

2022-02-15

Page views

5778

Article views/downloads

629

DOI

10.5603/EP.a2021.0110

Pubmed

35381103

Bibliographic record

Endokrynol Pol 2022;73(1):35-42.

Keywords

aripiprazole
chronic schizophrenia
leptin

Authors

Jarosław Sobiś
Łukasz Kunert
Monika Rykaczewska-Czerwińska
Elżbieta Świętochowska
Piotr Gorczyca

References (44)
  1. Meyer JM, McEvoy JP, Davis VG, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 2009; 66(11): 1013–1022.
    CrossRefPubMed
  2. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011; 14(7): 997–1012.
    CrossRefPubMed
  3. O'Connell KE, Thakore J, Dev KK. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr Res. 2014; 156(1): 1–8.
    CrossRefPubMed
  4. Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology. 2009; 34(1): 118–128.
    CrossRefPubMed
  5. Löffler S, Löffler-Ensgraber M, Fehsel K, et al. Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol. 2010; 25(2): 101–106.
    CrossRefPubMed
  6. Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014; 9(4): e94112.
    CrossRefPubMed
  7. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 2007; 32(4): 765–772.
    CrossRefPubMed
  8. Albaugh VL, Judson JG, She P, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2011; 16(5): 569–581.
    CrossRefPubMed
  9. Starrenburg FCJ, Bogers JP. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry. 2009; 24(3): 164–170.
    CrossRefPubMed
  10. Newcomer JW, Lieberman JA, Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004; 26(12): 1936–1946.
    CrossRefPubMed
  11. Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008; 6(3): 343–368.
    CrossRefPubMed
  12. Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014; 37(4): 1337–1353.
    CrossRefPubMed
  13. Stachowicz M, Janas-Kozik M, Olszanecka-Glinianowicz M, et al. Rola leptyny w zaburzeniach odżywiania się – współczesne poglądy. Psychiatr Pol. 2013; 47(5): 897–907.
  14. Van Harmelen V, Reynisdottir S, Eriksson P, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes. 1998; 47(6): 913–917.
    CrossRefPubMed
  15. Couillard C, Mauriège P, Prud'homme D, et al. Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia. 1997; 40(10): 1178–1184.
    CrossRefPubMed
  16. Fernández-Riejos P, Najib S, Santos-Alvarez J, et al. Role of leptin in the activation of immune cells. Mediators Inflamm. 2010; 2010: 568343.
    CrossRefPubMed
  17. Chen Ke, Li F, Li Ji, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006; 12(4): 425–432.
    CrossRefPubMed
  18. Wang S, Reed DB, Goli S, et al. Blood leptin and C-reactive protein provide more sensitive assessment than blood lipids and other inflammatory biomarkers in overweight university students. Nutr Res. 2011; 31(8): 586–593.
    CrossRefPubMed
  19. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009; 54(9): 1847–1856.
    CrossRefPubMed
  20. Sentissi O, Epelbaum J, Olié JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull. 2008; 34(6): 1189–1199.
    CrossRefPubMed
  21. Endomba FT, Tankeu AT, Nkeck JR, et al. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis. 2020; 19(1): 22.
    CrossRefPubMed
  22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
    CrossRefPubMed
  23. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012; 36(2): 286–294.
    CrossRefPubMed
  24. Kyle UG, Schutz Y, Dupertuis YM, et al. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition. 2003; 19(7-8): 597–604.
    CrossRefPubMed
  25. Guerrero-Romero F, Bermudez-Peña C, Rodríguez-Morán M. Severe hypomagnesemia and low-grade inflammation in metabolic syndrome. Magnes Res. 2011; 24(2): 45–53.
    CrossRefPubMed
  26. Faty A, Ferré P, Commans S. The acute phase protein Serum Amyloid A induces lipolysis and inflammation in human adipocytes through distinct pathways. PLoS One. 2012; 7(4): e34031.
    CrossRefPubMed
  27. Askari H, Tykodi G, Liu J, et al. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. J Clin Endocrinol Metab. 2010; 95(8): 3836–3843.
    CrossRefPubMed
  28. Maachi M, Piéroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004; 28(8): 993–997.
    CrossRefPubMed
  29. Sobiś J, Rykaczewska-Czerwińska M, Świętochowska E, et al. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep. 2015; 67(2): 353–359.
    CrossRefPubMed
  30. Phillips CM, Tierney AC, Perez-Martinez P, et al. Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring). 2013; 21(1): E154–E161.
    CrossRefPubMed
  31. Sharpe JK, Byrne NM, Stedman TJ, et al. Comparison of clinical body composition methods in people taking weight-inducing atypical antipsychotic medications. Asia Pac J Clin Nutr. 2008; 17(4): 573–579.
    PubMed
  32. Sugawara N, Yasui-Furukori N, Tsuchimine S, et al. Body composition in patients with schizophrenia: Comparison with healthy controls. Ann Gen Psychiatry. 2012; 11(1): 11.
    CrossRefPubMed
  33. Konarzewska B, Stefańska E, Wendołowicz A, et al. Visceral obesity in normal-weight patients suffering from chronic schizophrenia. BMC Psychiatry. 2014; 14: 35.
    CrossRefPubMed
  34. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012; 18(3): 363–374.
    CrossRefPubMed
  35. Takeuchi H, Uchida H, Suzuki T, et al. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry Clin Neurosci. 2010; 64(1): 104–106.
    CrossRefPubMed
  36. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006; 163(10): 1821–1825.
    CrossRefPubMed
  37. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry. 2007; 68(10): 1510–1516.
    CrossRefPubMed
  38. Virtanen KA, Iozzo P, Hällsten K, et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes. 2005; 54(9): 2720–2726.
    CrossRefPubMed
  39. Skrede S, Fernø J, Vázquez MJ, et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol. 2012; 15(2): 163–179.
    CrossRefPubMed
  40. Im SS, Kwon SK, Kang SY, et al. Regulation of GLUT4 gene expression by SREBP-1c in adipocytes. Biochem J. 2006; 399(1): 131–139.
    CrossRefPubMed
  41. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond). 2009; 33(1): 151–156.
    CrossRefPubMed
  42. Hivert MF, Sun Q, Shrader P, et al. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia. 2009; 52(10): 2101–2108.
    CrossRefPubMed
  43. Bosch M, Lopez-Bermejo A, Vendrell J, et al. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia. 2005; 48(9): 1841–1843.
    CrossRefPubMed
  44. Novick D, Dinarello CA, Dinarello CA, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999; 10(1): 127–136.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl